Adding Chemotherapy to Osimertinib Extends Progression-Free Survival in Dual-Mutant Lung Cancer

For the roughly one-third of EGFR-mutated lung cancer patients who also carry TP53 mutations — a genomic co-occurrence historically linked to faster resistance and worse outcomes — the question of whether adding chemotherapy to targeted therapy can meaningfully shift survival trajectories has been a clinical priority. This trial provides some of the clearest prospective evidence yet on that question.

The randomized trial published in JAMA evaluated osimertinib combined with platinum-based chemotherapy versus osimertinib monotherapy specifically in patients with advanced non-small cell lung cancer (NSCLC) harboring both EGFR and concurrent TP53 mutations. The co-mutation subgroup is clinically important because TP53 alterations — the most commonly mutated tumor suppressor gene in human cancer — are associated with accelerated development of osimertinib resistance mechanisms, including MET amplification and EGFR C797S emergence. The combination arm demonstrated a statistically meaningful improvement in progression-free survival, suggesting that upfront cytotoxic pressure may delay or suppress the clonal dynamics that drive resistance in this higher-risk population.

This finding carries nuanced implications. Osimertinib is already a third-generation EGFR inhibitor that outperformed earlier-generation agents in the landmark FLAURA trial, and the FLAURA2 trial had previously suggested a broader chemotherapy combination benefit across unselected EGFR-mutant NSCLC. What this trial advances is biomarker stratification — identifying TP53 co-mutation as a specific genomic context where the combination strategy may be most justified, potentially sparing patients without TP53 alterations from added chemotherapy toxicity. Key limitations include whether overall survival benefits will materialize at longer follow-up and the added toxicity burden, which matters significantly in quality-of-life calculations for patients. This is an incrementally important but genuinely practice-informing finding for thoracic oncologists managing genomically complex NSCLC.